Analyst Research Report Snapshot

Title:

Concall Update | Sun Pharmaceuticals Ltd.

Price:

$23.00

Provider:

IndiaNivesh Securities Pvt Ltd

Date:

10 Feb 2013

Pages:

3

Type:

AcrobatPDF

Companies referenced:

SUN.NS

Available for Immediate Download
Summary:

 Concall Update Sun Pharmaceuticals Ltd. | Company has reported robust revenue growth & sequential improvement in operating margins in the last 4-5 quarters on the back of better realization of certain derma products by Taro, favorable currency movement & supply of Doxil to US market. During the quarter, once again Taro reported healthy revenue growth with stable Gross margins & improvement in EBITDA margins, which indicates sustainability in increased price of Taro’s certain products. ANDA approval for Doxil has cleared uncertainties for supply of the product in US market. Current acquisition of DUSA Pharma, in our view, may take longer period to generate accretive results for the company, however we believe that URL acquisition would provide impetus to SUN’s revenue. Further, company is likely to launch generic version of Prandin (Anti-diabetic drug from Novo Nordisk, market Size ~$200 mn) in June 2013, with 180 days exclusivity, where company has received favorable verdict from court. Further, Management’s strong execution capabilities, strong balance sheet & continuous free cash flow generation ability of the company justify its premium valuations. We maintain HOLD rating on the stock & revise target price upward to Rs 796 (Valuing at 23x of FY14E). At CMP of Rs 750, the stock is trading at P/E multiple of 25.3x of FY13E & 21.7x of FY14E earnings estimates.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.